Life Insurance with Multiple Sclerosis | MS Life Insurance

Multiple sclerosis (MS) is one of the more complex neurological conditions in life insurance underwriting because outcomes vary so dramatically based on disease type and progression. Relapsing-remitting MS (RRMS) with infrequent relapses and minimal disability may qualify for coverage at a table rating; progressive forms of MS with significant disability typically result in decline at standard carriers. MS type, relapse frequency, functional disability level, and current treatment are the variables that drive everything.

What Underwriters Evaluate for Multiple Sclerosis

Every MS case is reviewed individually. These are the factors that determine whether you qualify, at what rating, and with which carrier:

MS Type — Relapsing-remitting MS (RRMS) is viewed most favorably, particularly when relapses are infrequent and well-controlled on disease-modifying therapy. Secondary progressive MS (SPMS) and primary progressive MS (PPMS) typically result in decline at most standard carriers due to the progressive nature of disability.

Relapse Frequency — The number of relapses in the past 2–5 years is a key metric. No relapses in the past 2 years with stable MRI is viewed most favorably. Frequent relapses (2+ per year) significantly worsen the underwriting outcome regardless of recovery.

Functional Disability Level (EDSS Score) — The Expanded Disability Status Scale (EDSS) is referenced by many underwriters. EDSS of 0–3 (minimal to moderate disability, fully ambulatory) is most insurable. EDSS of 4–5 (moderate disability, some walking limitation) results in table ratings or decline. EDSS above 5 typically results in decline at standard carriers.

Current Treatment and Compliance — Active use of FDA-approved disease-modifying therapies (DMTs) such as interferons, natalizumab, or ocrelizumab is viewed positively. It demonstrates engagement with treatment and potentially better disease control. Non-treatment or non-compliance raises concern.

Age at Diagnosis and Duration — Earlier age of onset and longer disease duration with minimal progression is viewed favorably — it suggests a more benign disease course. Recent diagnosis requires a waiting period at most carriers to assess stability.

MS Profile: General Underwriting Outlook

MS Profile	Typical Rating	Best Achievable	Notes
RRMS, no relapses 2+ years, EDSS 0–2	Table 4–6	Table 4 at select carriers	Most favorable MS presentation; stable and minimal disability
RRMS, 1–2 relapses in past 3 years, EDSS 2–3	Table 6–8	Table 6 at competitive carriers	Active but mild disease; limited options
RRMS, frequent relapses or EDSS 4+	Decline at most carriers	Simplified or guaranteed issue	Significant disability or active disease limits options severely
Progressive MS (SPMS or PPMS)	Decline	Guaranteed issue only	Progressive forms are declined at virtually all standard carriers

Guidelines current as of 2025–2026. Verify with us before applying.

Situations That Typically Result in Decline

Progressive MS (SPMS or PPMS) — Any progressive form of MS results in decline at virtually all fully underwritten carriers. The inherent progressive nature of disability makes standard coverage unavailable. Guaranteed issue products remain an option.

Significant Functional Disability (EDSS 5+) — Moderate to severe disability, particularly impaired ambulation requiring aids, results in decline at most standard carriers regardless of MS type.

Frequent Recent Relapses — Multiple relapses within the past 12–24 months signal active, poorly controlled disease and result in postponement or decline at most carriers until a period of stability is established.

What You Can Do to Improve Your Outcome

Stay current with disease-modifying therapy. Active treatment demonstrates engagement and potentially better disease control. Carriers view compliant, treated MS more favorably than untreated disease.

Apply during a period of documented stability. A relapse-free period of 12–24 months with stable MRI findings is the single most important factor in improving your underwriting outcome. Timing your application strategically makes a significant difference.

Work with a broker who knows MS underwriting. The spread between the most and least competitive carrier for MS can be several table ratings or the difference between insurable and declined. Informal shopping before formal application is essential.

Have MS? Let’s Find Your Coverage Options.

MS underwriting is highly carrier-dependent. We identify which carriers are most competitive for your specific disease profile before any formal application is submitted.

Call 1-888-972-0024

Browse All High-Risk Conditions

Understanding Your Rating: Life Insurance Risk Classifications | Table Ratings Explained (B–J) | Flat Extra Ratings

Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.

Frequently Asked Questions

Can I get life insurance with multiple sclerosis?

Yes, in many cases. Relapsing-remitting MS (RRMS) with infrequent relapses, minimal disability (low EDSS score), and active disease-modifying therapy can qualify for coverage at table ratings at select carriers. Progressive forms of MS (SPMS or PPMS) and cases with significant functional disability typically result in decline at standard fully underwritten carriers.

What MS factors most affect life insurance underwriting?

The most important factors are MS type (RRMS vs. progressive), relapse frequency over the past two to five years, functional disability level as measured by the Expanded Disability Status Scale (EDSS), and current treatment status. RRMS with no relapses in two or more years and an EDSS score of 0 to 3 is the most favorable presentation. Progressive MS or EDSS above 5 typically results in decline at standard carriers.

What is the best rate class achievable with MS?

The best achievable outcome for MS is typically Table 4 at select carriers for applicants with RRMS, no relapses in two or more years, minimal disability, and active disease-modifying therapy. Higher disability levels or more frequent relapses result in Table 6 to Table 8 or decline depending on the carrier.

Does disease-modifying therapy for MS help or hurt my life insurance application?

Active use of FDA-approved disease-modifying therapies (DMTs) for MS is viewed positively by underwriters. It demonstrates engagement with treatment and potentially better disease control. Non-treatment or non-compliance with prescribed therapy raises more concern than the medications themselves. Carriers want to see that your MS is being actively managed.

When is the best time to apply for life insurance with MS?

The best time to apply is during a documented period of stability — ideally after 12 to 24 months without a relapse, with stable MRI findings, and on a consistent disease-modifying therapy regimen. Applying during or shortly after a relapse typically results in postponement. Timing your application strategically relative to disease activity is one of the most effective ways to improve your underwriting outcome.

Life Insurance with Multiple Sclerosis | MS Life Insurance | High Risk